Experience With Tocilizumab, an Interleukin 6 Inhibitor, Used for the Treatment of Giant Cell Arteritis With Severe Comorbidity

Бекетова, Т. В.; Ushakova, M.A.; Никишина, Н. Ю.; Khelkovskaia-Sergeeva, A.; Николаева, Е. В.; Сажина, Е. Г.; Новоселова, Т. М.; Насонов, Е. Л.

doi:10.14412/1995-4484-2018-228-234

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10. Investigate the potential to extend indications for olokizumab, taking into account the positive experience with IL-6 inhibitors (tocilizumab) for the treatment of giant cell arteritis, [138][139][140] Takayasu arteritis, 141 juvenile idiopathic arthritis, 142 adult Still's disease, 143 early systemic scleroderma, 118,119 autoinflammatory syndromes (familial Mediterranean fever, Behcet's disease, TNF-associated periodic syndrome) 144 , hyperinflammatory syndromes, macrophage activation syndrome, haemophagocytic lymphohistiocytosis, chimeric antigen R-T-cell therapy, COVID-19 and persistent inflammation, immunosuppression and catabolism syndrome.…”

Section: Prospects For the Future Development Of Olokizumabmentioning

confidence: 99%

Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

Feist¹,

Насонов²

2023

Rheumatology

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic immunoinflammatory rheumatic disease, which manifests as progressive destruction of joints, systemic inflammation of visceral organs and a wide range of comorbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other immunoinflammatory rheumatic diseases, the role of interleukin (IL) 6 is of special interest. The introduction of the monoclonal antibodies tocilizumab and later sarilumab, both of which block the IL-6 receptor, into clinical practice was an important achievement in the treatment of immunoinflammatory rheumatic diseases at the beginning of the 21st century. The humanized monoclonal antibody against IL-6, olokizumab, provides a new mode of action by direct inhibition of IL-6. This article reviews new data on the efficacy and safety of olokizumab in RA and the prospects of its use in rheumatology.

show abstract

Section: Prospects For the Future Development Of Olokizumabmentioning

confidence: 99%

Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

Feist¹,

Насонов²

2023

Rheumatology

View full text Add to dashboard Cite

show abstract

“…Speaking of TCZ for GCA with severe comorbidities, let's cite the conclusion by Т. V. Beketova et al (2018) about «the potential effectiveness of short courses and small doses…, with which, probably, it is preferable to begin treatment in elderly patients with risk factors for adverse reactions» [91]. Adjuvant TCZ-therapy in the elderly patients with GCA may also have an advantage like influence upon depressive disorders [8].…”

Section: Consider Alternative Diagnosismentioning

confidence: 99%

Гигантоклеточный Артериит: Доказанные И Дискуссионные Аспекты Лечения

Lyzikov¹,

Puzanova²,

Лызиков³

2021

PJS

View full text Add to dashboard Cite

Giant cell arteritis is the most common systemic vasculitis in adults and especially in older people. Its development and treatment is often associated with comorbidities, relapses and va rious complications. The paper represents an analytical review, systema tic generalization and discussion of evidence on modern strategies, main risks, medicines and outcomes of the treatment of patients with giant cell arteritis. We studied specialized literature data published in English, Russian and German, found by electronic and manual search, checked for indexing in the main computer databa ses of evidence-based medicine (Cochrane Library and Medline) and selected without time limiting. Special attention is paid to prevention of early and severe complications and adverse effects of therapy -eye, cardiovascular, cerebrovascular and infectious diseases, diabetes, osteoporosis, fractures and malignancies. Best practice and the results of the introduction of an accelerated approach to management of a patient with suspected giant cell arteritis in primary healthcare setting are described, as well as current evidence base and prospects for early diagnosis and use of glucocorticoids and adjuvant immunosuppressive and biologic therapy with a focus on methotrexate and tocilizumab. Main principles, recommendations and evidence base of the 2020 British Society for Rheumatology guidelines on diagnosis and treatment of this vasculitis are represented and discussed.

show abstract

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Насонов

Feist

2022

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other IMRDs, the role of interleukin (IL) 6 is of special interest. The introduction of mAbs tocilizumab (TCZ) and later sarilumab (SAR), both blocking the receptor of this cytokine, into clinical practice was an important achievement in the treatment of IIRDs at the beginning of the 21st century. As a novel approach in the treatment of RA, the humanized mAb against IL-6 olokizumab (OKZ) is in development by the Russian company R-PHARM under the license agreement with UCB Pharma. The review examines new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatology

show abstract

Experience With Tocilizumab, an Interleukin 6 Inhibitor, Used for the Treatment of Giant Cell Arteritis With Severe Comorbidity

Cited by 3 publications

References 22 publications

Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

Гигантоклеточный Артериит: Доказанные И Дискуссионные Аспекты Лечения

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Contact Info

Product

Resources

About